Roger Perlmutter, Merck
March 18, 2021 08:58 AM EDTUpdated 10:24 AM
Bioregnum
China
Opinion

Roger Perl­mut­ter’s lat­est ‘re­tire­ment’ gig opens a door to the bustling Chi­na biotech scene

Roger Perl­mut­ter will be do­ing some glo­be­trot­ting for the next chap­ter in his long-run­ning bio­phar­ma bio — though the ac­tu­al trav­el part may be on hold …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Unit­ed­Health Group CEO An­drew Wit­ty steps down

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

HHS fo­cus­es on 'trans­paren­cy' in third-round IRA ne­go­ti­a­tion guid­ance

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

A service from the Financial Times
OSZAR »